GlassScriptPhysician profile
Stephen C Threlkeld
NPI 1578530895
$27,368.17
in general payments reported to CMS, 2019-2025
34 companies · $995 in 2025
The $995 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,112 · 2020: $1,386 · 2021: $1,191 · 2022: $1,568 · 2023: $1,460 · 2024: $18K · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $17K · Food and Beverage: $3,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $16,800.00 |
| Food and Beverage | $3,311.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $16,858.16 | 2023-2024 | |
| Gilead Sciences, INC. | $1,579.58 | 2019-2025 | |
| Abbvie INC. | $1,094.75 | 2019-2025 | Avycaz, Dalvance, Teflaro |
| Merck Sharp & Dohme LLC | $1,005.68 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Insmed, INC. | $928.79 | 2019-2025 | Arikayce, Brinsupri |
| Viiv Healthcare Company | $862.82 | 2019-2025 | Dovato |
| Astellas Pharma US INC | $860.43 | 2019-2025 | Cresemba |
| Triad Life Sciences INC. | $760.02 | 2021-2022 | |
| Cipla USA INC. | $495.43 | 2019 | |
| La Jolla Pharmaceutical Company | $370.17 | 2020-2025 | Xacduro, Xerava, Zevtera |
| Allergan, INC. | $342.88 | 2019-2020 | |
| Pfizer INC. | $340.23 | 2019-2025 | |
| Tetraphase Pharmaceuticals, INC. | $262.07 | 2019-2020 | |
| Theratechnologies INC. | $221.58 | 2019-2023 | Trogarzo, Egrifta |
| Melinta Therapeutics, LLC | $154.10 | 2019-2023 | Vabomere, Kimyrsa, Rezzayo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $142.70 | 2019-2021 | |
| Abbott Laboratories | $141.42 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Biotissue Holdings INC. | $138.23 | 2023 | |
| Mayne Pharma Commercial LLC | $129.87 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $125.94 | 2019-2020 | |
| Vyera Pharmaceuticals, LLC | $106.72 | 2019-2020 | |
| Shionogi INC | $80.68 | 2023-2024 | Fetroja |
| Organogenesis INC. | $60.68 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $54.15 | 2022-2023 | Rebyota |
| Emd Serono, INC. | $53.54 | 2019-2020 | |
| Smith+Nephew, INC. | $42.38 | 2022-2025 | Collagenase Santyl |
| Paratek Pharmaceuticals, INC. | $37.80 | 2019-2022 | |
| Csl Behring | $22.14 | 2019 | |
| Dynavax Technologies Corporation | $20.30 | 2023 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $20.07 | 2022 | |
| Grifols USA, LLC | $14.87 | 2021 | |
| Kci USA, INC. | $14.39 | 2019 | |
| Medela LLC | $13.20 | 2020 | |
| Mylan Institutional INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Threlkeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.